The role of diffusion-weighted MRI in assessment of response to chemotherapy in osteosarcoma

• Main Authors: Tarek Ahmed Raafat, Randa Osama Kaddah, Lobna Mohamed Bokhary, Hend Ali Sayed, Ahmed Sayed Awad
• Format: Article
• Language: English
• Published: SpringerOpen 2021-01-01
• Series: The Egyptian Journal of Radiology and Nuclear Medicine
• Subjects: Diffusion MRI; Response to chemotherapy; Osteosarcoma
• Online Access: https://doi.org/10.1186/s43055-020-00392-y

Abstract Background The most effective treatment for osteosarcoma is neoadjuvant chemotherapy along with surgical resection of the tumor. The prognosis significantly correlates with the degree of tumor necrosis following preoperative chemotherapy. The tumor necrosis will result in loss of the cell membrane integrity and expansion of the extracellular diffusion space which can be detected as an increase in the mean ADC value. The aim of our work is to evaluate the use of diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) value measurement for monitoring the therapeutic response after chemotherapy in osteosarcoma. Results This study included 25 cases of osteosarcoma: 15 males and 10 females. The age of the patients ranged from 7 to 46 years with mean age 22 years. All were assessed by magnetic resonance imaging (MRI) including DWI and the mean and minimum ADC values were calculated before and after chemotherapy. Follow-up DWI post-therapy revealed a rise in mean ADC value in 17 patients who considered having good response. The ADC value had been raised from 1.05 ± 0.4 × 10−3 mm2/s to 1.82 ± 0.45 × 10−3 mm2/s (P < 0.027) that is statistically moderately significant. In 8 patients, the post-therapy ADC value was similar to that of pre- or with a little change and they were considered having poor response. It showed changes from 1.29 ± 0.35 × 10−3 mm2/s to 1.32 ± 0.36 × 10−3 mm2/s (P > 0.05) that means no significant difference. Conclusion DWI and ADC value measurement play an important role in monitoring the therapeutic response after chemotherapy in osteosarcoma patients by comparing the mean ADC values before and after treatment.